SWOG at ASCO 2026

ASCO’s 2026 annual meeting is next week, which means another chance for SWOG to shine. Most meeting abstracts were posted to the ASCO website last evening, including at least 28 that report on work SWOG led or co-led. Six of these abstracts will be delivered as oral presentations.

Among the six, our GI committee has two randomized phase 2 trials reporting primary results:

• S2001 initial findings will be delivered by study chair Dr. Vincent Chung. S2001 compared olaparib with pembrolizumab to olaparib alone in patients with metastatic pancreatic cancer who had germline mutations in BRCA1 or BRCA2 (abstract 4012).
   
• S2107 study chair Dr. Van Morris will present initial findings from that trial of encorafenib plus cetuximab with or without nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer (abstract 3504).

Dr. Lucia Nappi (S1823) will present the first interim analysis of that trial, an observational study assessing the use of circulating miRNA 371 for predicting active germ cell malignancies in patients with testicular cancer (abstract LBA5003).

SWOG’s landmark S1609 DART trial, which has been publishing primary findings for individual rare cancer cohorts at a prodigious rate, will give us the big picture in Chicago, where DART co-PI Dr. Sandip Patel will present comprehensive results (spoiler alert: they include promising activity in a number of additional rare tumor types, along with practical lessons about conducting clinical trials in rare tumors – abstract 2502).

SWOG investigator Nam Nguyen-Hoang, MS, will deliver an oral presentation on the association of baseline vitamin D insufficiency with taxane-induced peripheral neuropathy in patients enrolled to our S1714 trial (abstract 12012).

Our sixth oral presentation is slated for a Clinical Science Symposium titled “Applying AI for Smarter, More Accessible Cancer Care.” Dr. Corey Speers will present on work applying a multimodal AI model to clinical and pathologic data from SWOG S8814 to identify which patients were most likely to benefit from adjuvant chemotherapy (abstract 107).

Complementing these SWOG oral presentations at ASCO are too many great posters to list in one Front Line, but we’ve compiled them all here, with session titles, times, and locations.

SWOG study chairs are also working hard to keep up awareness of their ongoing trials, presenting Trials-in-Progress (TIPs) posters for six studies in Chicago (including three Lung-MAP sub-studies):

• S1800E, Lung-MAP’s non-match sub-study (abstract TPS8669)
• S1900G, in EGFR-mutant, MET-amplified advanced NSCLC (abstract TPS8677)
• S1900J, in MET-amplified advanced NSCLC (abstract TPS8680)
• S2414 INSIGHT, in early-stage NSCLC (abstract TPS8131)
• S2433, in advanced pancreatic ductal adenocarcinoma (abstract TPS4264)
• SWOG/CCTG-PR26 TRIPLE SWITCH, in metastatic castration-sensitive prostate cancer (abstract TPS5149)

Of course, SWOG members are also represented as co-authors on numerous other abstracts as well, related to NCTN or NCORP trials conducted by other groups. And, as always, members contribute in a variety of venues.

SWOG's chief medical officer and chair emeritus, Dr. Charles Blanke, for example, will present "Modern Approaches to Medical Assistance in Dying: Procedures and Pharmacological Protocol" as part of an education session on End-of-Life Choices Around the Globe, and will moderate the session’s discussion panel.

And SWOG’s kidney cancer patient advocate, Laura Esfeller, MA, has been tapped for ASCO Featured Voices, a group of about a dozen influencers ASCO asks to share expert insights and meeting updates on social media (@LauraEsfeller on Twitter/X or @calicajun87 on Instagram).

This Front Line has become one of our longer posts, but it only begins to scratch the surface of the breadth and depth of the SWOG work at ASCO’s 2026 annual meeting. Check out our full list of SWOG-related abstracts to do a deeper dive.

And if there’s content you can’t catch live (or live-streamed), we do have a “Best of SWOG at ASCO(s)” webinar in the works. More on this soon.

We hope to see many of you in Chicago next week!